Joel Greenblatt Mirati Therapeutics, Inc. Transaction History

Gotham Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $297,682 - $485,607	10,708 New	10,708 $466,000
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $119,871 - $238,683	-1,581 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $16,633 - $23,976	126 Added 8.66%	1,581 $232,000
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $59,722 - $80,207	-452 Reduced 23.7%	1,455 $257,000
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $56,592 - $70,633	393 Added 25.96%	1,907 $308,000
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $171,475 - $253,246	1,514 New	1,514 $251,000
Q1 2020 May 15, 2020	SELL	$69.78 - $116.21 $134,535 - $224,052	-1,928 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $136,425 - $248,442	1,928 New	1,928 $248,000
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $265,517 - $373,516	-3,408 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$59.49 - $104.71 $27,246 - $47,957	-458 Reduced 11.85%	3,408 $351,000
Q1 2019 May 15, 2019	BUY	$43.65 - $78.95 $168,750 - $305,220	3,866 New	3,866 $283,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.